ZYME

Latest SEC Filings & News for ZYME

1 most recent filing and news item mentioning ZYME. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day
curl "https://api.brieftape.com/v1/tickers/ZYME/news?limit=20"

Pull ZYME filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day
RegulatoryAug 25, 2026Positive

Zymeworks' zanidatamab-hrii gains FDA approval for first-line HER2+ gastroesophageal cancer

Zymeworks announced the FDA approved a Ziihera plus tislelizumab and chemotherapy regimen for first-line HER2-positive gastroesophageal adenocarcinoma, boosting its diversified collaboration strategy.

View filing at SEC.gov →
AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.